Ying Cao, MD
Hematology/Oncology · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 058189 · Adventist Health Mendocino Coast · Novato Community Hospital · Providence Santa Rosa Memorial Hospital · Sutter Lakeside Hospital · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Cao’s office at (707) 521-7750 to ask if they take your plan before you enroll.
California Medical Board record
Licence A123342 · Current
Licensed to practise in California · since 2012 · expires 2026-10-31 · Nanjing Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Mendocino CoastFort Bragg, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 5 of 5 · 80% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
- Sutter Lakeside HospitalLakeport, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Mendocino Coast
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for heart failure patientsComplications and deaths | 9 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 103 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 268 cases | None | Jul 2024 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 78 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -24.2 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.7 · 102 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 101 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.7 (5.2 to 11.1) · 65 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.3 to 14.6) · 65 cases | No different | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.8 to 17.4) · 526 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 48 cases | No different | Jan 2024 – Dec 2024 |
What patients said (119 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 5 |
| Communication about medicines | 4 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 86% |
| Nurses "always" communicated well | 86% |
| Doctors "always" communicated well | 89% |
| Staff "always" explained | 72% |
| Yes, staff "did" give patients this information | 94% |
| Yes, staff "did" give patients information about help after discharge | 94% |
| Doctors "always" explained things so they could understand | 85% |
| Doctors "always" listened carefully | 87% |
| Doctors "always" treated them with courtesy and respect | 96% |
| Patients who gave a rating of "9" or "10" (high) | 86% |
| Staff "always" explained new medications | 87% |
| Nurses "always" explained things so they could understand | 82% |
| Nurses "always" listened carefully | 84% |
| Nurses "always" treated them with courtesy and respect | 92% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 57% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Lakeside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.7 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 133 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 379 cases | None | Jul 2024 – Jun 2025 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 31 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.249 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.4 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 109 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.3) · 564 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (209 patients answered, 18% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 82% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 58% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$246,012
Medicare paid this office $246,012 for 757 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 611 | $112,755 | $99 |
| Long return visit (40+ min) | 157 | $92,164 | $150 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 594 | $18,288 | $14 |
| New patient visit (60+ min) | 61 | $10,711 | $176 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $5,960 | $142 |
See all 8 services
| Return visit (30+ min) | 611 | $112,755 | $99 |
| Long return visit (40+ min) | 157 | $92,164 | $150 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 594 | $18,288 | $14 |
| New patient visit (60+ min) | 61 | $10,711 | $176 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $5,960 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,527 | $97 |
| New patient visit (45+ min) | 13 | $1,873 | $144 |
| Short return visit (20+ min) | 18 | $1,111 | $58 |
Who their Medicare patients are
757 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 12% · Women 73% · Also on Medicaid 19% · Health risk score 1.72. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 64% · Cancer 54% · Chronic kidney disease 24% · Coronary heart disease 22% · Diabetes 21% · Depression 21% · Atrial fibrillation 19% · Heart failure 15% · COPD 15% · Stroke 9% · Dementia 6%.
The office billed $934,165, Medicare allowed $330,399 and paid $246,012; for 3,271 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 757 | 3,271 | 75 | 1.72 | $934,165 | $246,012 |
| 2023 | 812 | 2,254 | 75 | 1.61 | $969,026 | $276,488 |
| 2022 | 726 | 1,924 | 75 | 1.53 | $793,410 | $236,105 |
| 2021 | 586 | 1,599 | 74 | 1.53 | $657,423 | $201,349 |
| 2020 | 571 | 8,294 | 74 | 1.69 | $872,801 | $258,373 |
| 2019 | 837 | 177,425 | 73 | 1.75 | $9,924,866 | $3,175,795 |
| 2018 | 695 | 147,551 | 73 | 1.78 | $7,915,573 | $2,538,871 |
| 2017 | 486 | 29,995 | 72 | 1.80 | $2,147,211 | $618,935 |
| 2016 | 444 | 45,479 | 73 | 1.59 | $3,101,223 | $840,923 |
| 2015 | 271 | 21,332 | 77 | 2.17 | $1,021,359 | $336,673 |
| 2014 | 100 | 4,456 | 76 | 1.68 | $281,174 | $91,226 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 659 | $123,403 | $100 |
| Long return visit (40+ min) | 209 | $116,425 | $152 |
| New patient visit (60+ min) | 111 | $20,379 | $184 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,436 | $143 |
| New patient visit (45+ min) | 38 | $4,818 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,707 | $100 |
| Short return visit (20+ min) | 19 | $1,442 | $72 |
2022: 7 services
| Return visit (30+ min) | 568 | $109,936 | $103 |
| Long return visit (40+ min) | 215 | $94,702 | $154 |
| New patient visit (45+ min) | 75 | $10,237 | $136 |
| New patient visit (60+ min) | 50 | $8,835 | $177 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,806 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,151 | $86 |
| Short return visit (20+ min) | 18 | $1,442 | $72 |
2021: 7 services
| Long return visit (40+ min) | 235 | $98,363 | $146 |
| Return visit (30+ min) | 454 | $76,930 | $105 |
| New patient visit (45+ min) | 78 | $10,880 | $139 |
| New patient visit (60+ min) | 41 | $7,285 | $178 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,412 | $171 |
| Short return visit (20+ min) | 15 | $1,032 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,027 | $79 |
2020: 11 services
| Long return visit (40+ min) | 250 | $70,947 | $125 |
| Return visit (30+ min) | 353 | $44,179 | $77 |
| Telephone medical discussion with physician, 21-30 minutes | 71 | $8,666 | $95 |
| New patient visit (45+ min) | 69 | $8,119 | $118 |
| Telephone medical discussion with physician, 11-20 minutes | 87 | $7,030 | $64 |
| New patient visit (60+ min) | 36 | $6,189 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,407 | $86 |
| Short return visit (20+ min) | 41 | $2,273 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,901 | $173 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $1,657 | $127 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $557 | $37 |
2019: 41 services
| Injection, rituximab, 10 mg | 23 | $298,206 | None |
| Injection, nivolumab, 1 mg | 13 | $276,210 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $221,371 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 35 | $201,300 | None |
| Injection, denosumab, 1 mg | 68 | $131,715 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 14 | $122,943 | None |
| Return visit (30+ min) | 456 | $79,507 | $85 |
| Administration of chemotherapy into vein, 1 hour or less | 153 | $63,476 | $127 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 49 | $23,963 | $1 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $16,678 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 98 | $15,271 | $64 |
| Administration of chemotherapy into vein, each additional hour | 98 | $9,908 | $27 |
| Long return visit (40+ min) | 61 | $9,378 | $120 |
| New patient visit (60+ min) | 51 | $8,641 | $169 |
| New patient visit (45+ min) | 65 | $8,609 | $132 |
| Administration of prolonged chemotherapy into vein | 19 | $8,554 | $128 |
| Administration of additional new drug or substance into vein, 1 hour or less | 43 | $6,789 | $61 |
| Administration of additional new drug or substance into vein using push technique | 24 | $5,205 | $53 |
| Injection of additional new drug or substance into vein | 85 | $4,564 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,260 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $3,686 | $28 |
| Injection of drug or substance under skin or into muscle | 120 | $3,667 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $2,736 | $19 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $2,482 | $146 |
| Injection, leucovorin calcium, per 50 mg | 18 | $2,395 | None |
| Injection of drug or substance into vein | 48 | $2,304 | $35 |
| Short return visit (20+ min) | 32 | $1,980 | $60 |
| Injection, oxaliplatin, 0.5 mg | 15 | $1,815 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $1,626 | $28 |
| Injection, zoledronic acid, 1 mg | 27 | $1,297 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,184 | None |
| Collection of blood sample from implanted device | 29 | $1,047 | $21 |
| Injection, fluorouracil, 500 mg | 18 | $952 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $926 | $19 |
| Injection, carboplatin, 50 mg | 18 | $792 | None |
| Injection, paclitaxel, 1 mg | 15 | $720 | None |
| Irrigation of implanted venous access drug delivery device | 26 | $708 | $19 |
| Injection, ondansetron hydrochloride, per 1 mg | 58 | $253 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $216 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 11 | $118 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $46 | None |
2018: 43 services
| Injection, nivolumab, 1 mg | 14 | $213,187 | None |
| Injection, bevacizumab, 10 mg | 14 | $200,191 | None |
| Injection, rituximab, 100 mg | 17 | $158,845 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $149,397 | None |
| Injection, pegfilgrastim, 6 mg | 19 | $148,638 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 27 | $143,441 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17 | $102,336 | None |
| Injection, denosumab, 1 mg | 40 | $75,091 | None |
| Injection, tocilizumab, 1 mg | 13 | $74,643 | None |
| Return visit (30+ min) | 353 | $63,943 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 137 | $43,194 | $124 |
| New patient visit (60+ min) | 90 | $14,659 | $163 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 26 | $13,242 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | $11,872 | $63 |
| Long return visit (40+ min) | 78 | $11,477 | $116 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $8,063 | None |
| Administration of prolonged chemotherapy into vein | 16 | $7,589 | $126 |
| Administration of chemotherapy into vein, each additional hour | 71 | $6,220 | $27 |
| New patient visit (45+ min) | 48 | $6,187 | $129 |
| Injection, fosaprepitant, 1 mg | 11 | $5,548 | None |
| Administration of chemotherapy into vein using push technique | 14 | $5,349 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $4,929 | $59 |
| Injection of additional new drug or substance into vein | 88 | $4,550 | $16 |
| Administration of additional new drug or substance into vein using push technique | 25 | $4,394 | $51 |
| Injection of drug or substance under skin or into muscle | 98 | $3,980 | $18 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,073 | $85 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $2,116 | $27 |
| Injection, leucovorin calcium, per 50 mg | 15 | $2,045 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,884 | $19 |
| Short return visit (20+ min) | 24 | $1,649 | $61 |
| Injection, oxaliplatin, 0.5 mg | 12 | $1,491 | None |
| Injection, zoledronic acid, 1 mg | 22 | $1,377 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,120 | $27 |
| Injection, fluorouracil, 500 mg | 16 | $803 | None |
| Injection, paclitaxel, 1 mg | 16 | $799 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $771 | $18 |
| Injection, carboplatin, 50 mg | 17 | $613 | None |
| Collection of blood sample from implanted device | 12 | $550 | $20 |
| Irrigation of implanted venous access drug delivery device | 11 | $292 | $24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 69 | $208 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 51 | $164 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $28 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $15 | None |
2017: 23 services
| Return visit (30+ min) | 250 | $51,053 | $82 |
| Injection, pegfilgrastim, 6 mg | 11 | $45,531 | None |
| Injection, denosumab, 1 mg | 20 | $24,860 | None |
| New patient visit (60+ min) | 144 | $22,963 | $159 |
| Long return visit (40+ min) | 99 | $16,202 | $117 |
| Administration of chemotherapy into vein, 1 hour or less | 59 | $10,502 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $5,011 | $85 |
| Injection of additional new drug or substance into vein | 58 | $2,475 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 28 | $2,007 | $57 |
| Biopsy of bone marrow | 14 | $1,928 | $138 |
| Administration of chemotherapy into vein, each additional hour | 29 | $1,917 | $24 |
| Injection of drug or substance under skin or into muscle | 55 | $1,539 | $21 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $1,224 | $56 |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,141 | $81 |
| Short return visit (20+ min) | 18 | $968 | $54 |
| Collection of blood sample from implanted device | 30 | $783 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 17 | $705 | $26 |
| Administration of additional new drug or substance into vein using push technique | 11 | $638 | $53 |
| Injection, paclitaxel, 1 mg | 11 | $457 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $395 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $75 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $45 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 28 | $20 | None |
2016: 33 services
| Injection, pembrolizumab, 1 mg | 11 | $111,442 | None |
| Injection, nivolumab, 1 mg | 16 | $93,095 | None |
| Injection, rituximab, 100 mg | 12 | $64,694 | None |
| Injection, pegfilgrastim, 6 mg | 14 | $52,686 | None |
| Return visit (30+ min) | 183 | $33,901 | $88 |
| Injection, denosumab, 1 mg | 27 | $33,833 | None |
| New patient visit (60+ min) | 191 | $31,572 | $165 |
| Administration of chemotherapy into vein, 1 hour or less | 94 | $17,877 | $115 |
| Long return visit (40+ min) | 44 | $5,576 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,792 | $84 |
| Injection of additional new drug or substance into vein | 64 | $3,773 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 23 | $2,284 | $59 |
| Short return visit (20+ min) | 32 | $2,278 | $60 |
| Biopsy of bone marrow | 15 | $2,122 | $141 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $2,119 | $53 |
| Administration of prolonged chemotherapy into vein | 11 | $2,025 | $119 |
| Injection of drug or substance under skin or into muscle | 67 | $1,747 | $21 |
| Administration of chemotherapy into vein, each additional hour | 30 | $1,356 | $24 |
| Collection of blood sample from implanted device | 39 | $1,296 | $20 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,205 | $52 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $820 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $651 | $27 |
| Injection of drug or substance into vein | 11 | $575 | $48 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $568 | $26 |
| Injection, paclitaxel, 1 mg | 12 | $546 | None |
| Injection, carboplatin, 50 mg | 13 | $439 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $216 | $17 |
| Injection, fluorouracil, 500 mg | 11 | $199 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 13 | $134 | $10 |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $114 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 41 | $105 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $19 | None |
| Unclassified drugs | 15 | $15 | None |
2015: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 124 | $37,937 | $91 |
| Return visit (30+ min) | 115 | $31,185 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 98 | $18,103 | $177 |
| New patient visit (60+ min) | 46 | $8,124 | $177 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $4,585 | $131 |
| Long return visit (40+ min) | 29 | $3,903 | $130 |
| Short return visit (20+ min) | 33 | $3,459 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 50 | $2,551 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $1,944 | $29 |
| Injection of drug or substance under skin or into muscle | 13 | $1,230 | $25 |
| Insertion of needle into vein for collection of blood sample | 11 | $38 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $37 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $13 | None |
2014: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $12,084 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,634 | $180 |
| Return visit (30+ min) | 38 | $8,207 | $100 |
| New patient visit (60+ min) | 14 | $2,638 | $188 |
| Short return visit (20+ min) | 11 | $885 | $68 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 23 | $634 | $10 |
Medicaid work
$30,053 in 2024
Medicaid paid $30,053 for 578 billed services this clinician did in 2024, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 256 | $16,826 |
| Return visit (30+ min) | 322 | $13,227 |
| 2024 | 578 | 2 | 47 | $30,053 |
| 2023 | 1,044 | 2 | 49 | $59,861 |
| 2022 | 667 | 2 | 46 | $36,609 |
| 2021 | 511 | 2 | 36 | $28,071 |
| 2020 | 471 | 2 | 36 | $28,724 |
| 2019 | 560 | 5 | 41 | $32,500 |
| 2018 | 372 | 3 | 33 | $22,270 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 541 | $37,484 |
| Return visit (30+ min) | 503 | $22,377 |
2022
| Long return visit (40+ min) | 301 | $20,996 |
| Return visit (30+ min) | 366 | $15,614 |
2021
| Long return visit (40+ min) | 280 | $18,330 |
| Return visit (30+ min) | 231 | $9,741 |
2020
| Long return visit (40+ min) | 256 | $17,252 |
| Return visit (30+ min) | 215 | $11,472 |
2019
| Return visit (30+ min) | 408 | $26,069 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 89 | $4,654 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 34 | $1,633 |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $80 |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $63 |
2018
| Return visit (30+ min) | 260 | $16,576 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 80 | $4,020 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 32 | $1,674 |
Drugs they prescribed that Part D paid
$474,183
Pharmacies billed $474,183 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (69 of 2,025) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
1,792 generic and 233 brand-name prescriptions · $474,183 in drug cost · 94 antibiotic prescriptions to 41 people · 13 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | None | 12 | $160,982 | $13,415 |
| Eliquis | None | 63 | $51,250 | $813 |
| Privigen | Immune globulin | 14 | $49,497 | $3,535 |
| Xarelto | None | 42 | $34,419 | $820 |
| Creon | None | 14 | $11,431 | $817 |
See all 39 drugs
| Xtandi | None | 12 | $160,982 | $13,415 |
| Eliquis | None | 63 | $51,250 | $813 |
| Privigen | Immune globulin | 14 | $49,497 | $3,535 |
| Xarelto | None | 42 | $34,419 | $820 |
| Creon | None | 14 | $11,431 | $817 |
| Anastrozole | None | 346 | $6,544 | $19 |
| Exemestane | None | 32 | $4,560 | $143 |
| Atovaquone | None | 15 | $4,068 | $271 |
| Acyclovir | None | 121 | $1,886 | $16 |
| Prochlorperazine Maleate | None | 165 | $1,798 | $11 |
| Ondansetron | None | 80 | $1,733 | $22 |
| Dexamethasone | None | 56 | $1,574 | $28 |
| Hydroxyurea | None | 92 | $1,528 | $17 |
| Anagrelide | None | 15 | $1,299 | $87 |
| Tamoxifen Citrate | None | 81 | $1,256 | $16 |
| Zolpidem | None | 18 | $1,058 | $59 |
| Levothyroxine | None | 69 | $750 | $11 |
| Letrozole | None | 30 | $666 | $22 |
| Gabapentin | None | 53 | $366 | $7 |
| Prednisone | None | 42 | $357 | $8 |
| Potassium Chloride | None | 56 | $349 | $6 |
| Mirtazapine | None | 20 | $341 | $17 |
| Ondansetron Odt | None | 12 | $299 | $25 |
| Hydroxyzine | None | 11 | $274 | $25 |
| Sulfamethoxazole-Trimethoprim | None | 53 | $262 | $5 |
| Allopurinol | None | 29 | $248 | $9 |
| Hydrocodone-Acetaminophen | None | 29 | $216 | $7 |
| Oxycodone-Acetaminophen | None | 12 | $196 | $16 |
| Lidocaine-Prilocaine | None | 17 | $164 | $10 |
| Lorazepam | None | 32 | $150 | $5 |
| Furosemide | None | 57 | $148 | $3 |
| Diphenoxylate-Atropine | None | 14 | $131 | $9 |
| Folic Acid | None | 22 | $116 | $5 |
| Olanzapine | None | 12 | $100 | $8 |
| Sodium Chloride | None | 13 | $92 | $7 |
| Triamcinolone Acetonide | None | 11 | $87 | $8 |
| Levofloxacin | None | 17 | $75 | $4 |
| Pantoprazole | None | 17 | $61 | $4 |
| Tramadol | None | 14 | $22 | $2 |
Year by year
| 2024 | 2,025 | 355 | 3% (69) | 12% | $474,183 |
| 2023 | 1,865 | 365 | 3% (60) | None | $1,597,978 |
| 2022 | 1,720 | 301 | 5% (80) | None | $4,083,696 |
| 2021 | 1,388 | 251 | 3% (46) | 22% | $3,223,914 |
| 2020 | 1,220 | 236 | 4% (44) | 21% | $2,737,009 |
| 2019 | 918 | 203 | 3% (29) | 22% | $1,984,391 |
| 2018 | 700 | 157 | 10% (69) | 21% | $1,284,392 |
| 2017 | 721 | 134 | 14% (98) | 14% | $736,996 |
| 2016 | 541 | 123 | 12% (66) | 13% | $329,039 |
| 2015 | 262 | 58 | 13% (34) | 23% | $393,317 |
| 2014 | 145 | 32 | 10% (15) | 34% | $256,423 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Jakafi | 13 | $234,807 | $18,062 |
| Xarelto | 39 | $32,158 | $825 |
| Eliquis | 33 | $21,926 | $664 |
| Anastrozole | 352 | $9,827 | $28 |
| Exemestane | 30 | $8,940 | $298 |
| Abiraterone Acetate | 12 | $6,750 | $562 |
| Creon | 15 | $4,497 | $300 |
| Hydroxyurea | 89 | $2,671 | $30 |
| Anagrelide | 16 | $2,592 | $162 |
| Tamoxifen Citrate | 100 | $2,006 | $20 |
| Prochlorperazine Maleate | 125 | $1,768 | $14 |
| Letrozole | 59 | $1,601 | $27 |
| Dexamethasone | 63 | $1,578 | $25 |
| Ondansetron | 75 | $1,138 | $15 |
| Levothyroxine | 73 | $947 | $13 |
| Potassium Chloride | 69 | $915 | $13 |
| Ciprofloxacin | 15 | $714 | $48 |
| Acyclovir | 39 | $652 | $17 |
| Furosemide | 51 | $420 | $8 |
| Gabapentin | 41 | $376 | $9 |
| Duloxetine | 27 | $347 | $13 |
| Oxycodone-Acetaminophen | 19 | $341 | $18 |
| Levofloxacin | 11 | $322 | $29 |
| Pantoprazole | 22 | $315 | $14 |
| Hydrocodone-Acetaminophen | 24 | $289 | $12 |
| Olanzapine | 12 | $286 | $24 |
| Prednisone | 37 | $264 | $7 |
| Alendronate | 18 | $188 | $10 |
| Allopurinol | 12 | $181 | $15 |
| Diphenoxylate-Atropine | 13 | $160 | $12 |
| Folic Acid | 30 | $130 | $4 |
| Zolpidem | 20 | $115 | $6 |
| Lorazepam | 39 | $71 | $2 |
2022: 42 drugs
| Revlimid | 37 | $708,190 | $19,140 |
| Jakafi | 22 | $540,725 | $24,578 |
| Imbruvica | 29 | $449,433 | $15,498 |
| Ibrance | 24 | $370,580 | $15,441 |
| Cabometyx | 14 | $340,172 | $24,298 |
| Pomalyst | 11 | $246,479 | $22,407 |
| Tagrisso | 13 | $215,893 | $16,607 |
| Ninlaro | 17 | $202,028 | $11,884 |
| Sprycel | 11 | $189,042 | $17,186 |
| Verzenio | 12 | $180,247 | $15,021 |
| Xarelto | 41 | $27,322 | $666 |
| Eliquis | 18 | $14,372 | $798 |
| Anastrozole | 276 | $6,304 | $23 |
| Oxycontin | 11 | $3,307 | $301 |
| Creon | 11 | $2,003 | $182 |
| Tamoxifen Citrate | 80 | $1,989 | $25 |
| Prochlorperazine Maleate | 132 | $1,897 | $14 |
| Pregabalin | 12 | $1,703 | $142 |
| Hydroxyurea | 54 | $1,549 | $29 |
| Dexamethasone | 56 | $1,525 | $27 |
| Anagrelide | 12 | $1,518 | $127 |
| Ondansetron | 70 | $1,449 | $21 |
| Duloxetine | 16 | $737 | $46 |
| Potassium Chloride | 57 | $598 | $10 |
| Letrozole | 30 | $565 | $19 |
| Gabapentin | 53 | $448 | $8 |
| Levothyroxine | 28 | $441 | $16 |
| Venlafaxine Hcl Er | 18 | $438 | $24 |
| Prednisone | 35 | $412 | $12 |
| Acyclovir | 23 | $355 | $15 |
| Ondansetron Odt | 17 | $297 | $17 |
| Hydrocodone-Acetaminophen | 26 | $266 | $10 |
| Pantoprazole | 18 | $245 | $14 |
| Oxycodone-Acetaminophen | 14 | $223 | $16 |
| Allopurinol | 17 | $190 | $11 |
| Furosemide | 27 | $188 | $7 |
| Alendronate | 12 | $163 | $14 |
| Lorazepam | 32 | $124 | $4 |
| Sodium Chloride | 11 | $119 | $11 |
| Azithromycin | 12 | $106 | $9 |
| Sulfamethoxazole-Trimethoprim | 15 | $34 | $2 |
| Zolpidem | 11 | $29 | $3 |
2021: 29 drugs
| Revlimid | 31 | $584,331 | $18,849 |
| Ibrance | 42 | $568,088 | $13,526 |
| Ninlaro | 35 | $397,708 | $11,363 |
| Imbruvica | 26 | $373,301 | $14,358 |
| Tagrisso | 12 | $195,247 | $16,271 |
| Abiraterone Acetate | 19 | $51,242 | $2,697 |
| Xarelto | 34 | $17,307 | $509 |
| Imatinib Mesylate | 13 | $6,003 | $462 |
| Anastrozole | 270 | $5,347 | $20 |
| Anagrelide | 14 | $4,114 | $294 |
| Exemestane | 15 | $2,549 | $170 |
| Tamoxifen Citrate | 67 | $2,210 | $33 |
| Dexamethasone | 70 | $2,151 | $31 |
| Prochlorperazine Maleate | 97 | $1,236 | $13 |
| Ondansetron | 54 | $1,136 | $21 |
| Hydroxyurea | 23 | $1,086 | $47 |
| Acyclovir | 39 | $724 | $19 |
| Mirtazapine | 18 | $545 | $30 |
| Venlafaxine Hcl Er | 18 | $459 | $26 |
| Letrozole | 30 | $357 | $12 |
| Levothyroxine | 15 | $318 | $21 |
| Gabapentin | 31 | $276 | $9 |
| Prednisone | 34 | $273 | $8 |
| Hydrocodone-Acetaminophen | 18 | $222 | $12 |
| Lorazepam | 31 | $220 | $7 |
| Potassium Chloride | 14 | $93 | $7 |
| Zolpidem | 16 | $91 | $6 |
| Furosemide | 15 | $43 | $3 |
| Dextrose in Water | 11 | $32 | $3 |
2020: 22 drugs
| Ninlaro | 44 | $484,519 | $11,012 |
| Ibrance | 37 | $482,252 | $13,034 |
| Revlimid | 24 | $446,823 | $18,618 |
| Pomalyst | 16 | $305,436 | $19,090 |
| Imbruvica | 22 | $298,047 | $13,548 |
| Xarelto | 27 | $12,752 | $472 |
| Exemestane | 25 | $6,694 | $268 |
| Anastrozole | 272 | $6,218 | $23 |
| Hydroxyurea | 55 | $1,678 | $31 |
| Tamoxifen Citrate | 36 | $1,582 | $44 |
| Prochlorperazine Maleate | 104 | $1,297 | $12 |
| Dexamethasone | 46 | $1,080 | $23 |
| Ondansetron | 53 | $855 | $16 |
| Mirtazapine | 24 | $720 | $30 |
| Acyclovir | 32 | $695 | $22 |
| Letrozole | 24 | $458 | $19 |
| Prednisone | 37 | $293 | $8 |
| Hydrocodone-Acetaminophen | 29 | $260 | $9 |
| Pantoprazole | 11 | $213 | $19 |
| Gabapentin | 19 | $158 | $8 |
| Lorazepam | 22 | $58 | $3 |
| Zolpidem | 15 | $35 | $2 |
2019: 20 drugs
| Revlimid | 23 | $454,279 | $19,751 |
| Ninlaro | 24 | $259,841 | $10,827 |
| Imbruvica | 20 | $257,989 | $12,899 |
| Ibrance | 16 | $196,881 | $12,305 |
| Zytiga | 12 | $140,551 | $11,713 |
| Abiraterone Acetate | 13 | $57,024 | $4,386 |
| Xarelto | 30 | $16,204 | $540 |
| Exemestane | 18 | $5,899 | $328 |
| Anastrozole | 234 | $5,785 | $25 |
| Hydroxyurea | 47 | $1,427 | $30 |
| Tamoxifen Citrate | 22 | $854 | $39 |
| Prochlorperazine Maleate | 69 | $791 | $11 |
| Dexamethasone | 31 | $732 | $24 |
| Acyclovir | 33 | $572 | $17 |
| Ondansetron | 35 | $462 | $13 |
| Prednisone | 27 | $253 | $9 |
| Allopurinol | 11 | $182 | $17 |
| Hydrocodone-Acetaminophen | 15 | $124 | $8 |
| Potassium Chloride | 11 | $107 | $10 |
| Lorazepam | 20 | $82 | $4 |
2018: 14 drugs
| Revlimid | 29 | $399,958 | $13,792 |
| Ibrance | 28 | $321,979 | $11,499 |
| Xarelto | 13 | $6,715 | $517 |
| Anastrozole | 166 | $2,479 | $15 |
| Tamoxifen Citrate | 26 | $1,371 | $53 |
| Dexamethasone | 37 | $781 | $21 |
| Ondansetron | 40 | $445 | $11 |
| Hydrocodone-Acetaminophen | 25 | $293 | $12 |
| Prochlorperazine Maleate | 36 | $245 | $7 |
| Prednisone | 22 | $189 | $9 |
| Venlafaxine Hcl Er | 12 | $83 | $7 |
| Levofloxacin | 12 | $78 | $6 |
| Gabapentin | 12 | $56 | $5 |
| Lorazepam | 19 | $50 | $3 |
2017: 16 drugs
| Ibrance | 33 | $366,273 | $11,099 |
| Creon | 14 | $16,855 | $1,204 |
| Exemestane | 14 | $4,466 | $319 |
| Anastrozole | 162 | $1,785 | $11 |
| Tamoxifen Citrate | 47 | $1,424 | $30 |
| Morphine Sulfate Er | 19 | $766 | $40 |
| Ondansetron | 47 | $507 | $11 |
| Oxycodone-Acetaminophen | 28 | $506 | $18 |
| Prochlorperazine Maleate | 46 | $261 | $6 |
| Hydrocodone-Acetaminophen | 35 | $256 | $7 |
| Dexamethasone | 30 | $256 | $9 |
| Lorazepam | 36 | $170 | $5 |
| Hydroxyurea | 15 | $156 | $10 |
| Letrozole | 13 | $106 | $8 |
| Venlafaxine Hcl Er | 12 | $77 | $6 |
| Gabapentin | 12 | $44 | $4 |
2016: 12 drugs
| Ibrance | 14 | $147,369 | $10,526 |
| Anastrozole | 132 | $1,512 | $11 |
| Hydrocodone-Acetaminophen | 31 | $792 | $26 |
| Tamoxifen Citrate | 18 | $364 | $20 |
| Oxycodone-Acetaminophen | 13 | $349 | $27 |
| Ondansetron | 34 | $321 | $9 |
| Dexamethasone | 17 | $215 | $13 |
| Letrozole | 18 | $208 | $12 |
| Prochlorperazine Maleate | 36 | $190 | $5 |
| Prednisone | 13 | $165 | $13 |
| Gabapentin | 12 | $94 | $8 |
| Lorazepam | 28 | $88 | $3 |
2015: 5 drugs
| Tarceva | 14 | $93,743 | $6,696 |
| Anastrozole | 33 | $396 | $12 |
| Hydrocodone-Acetaminophen | 19 | $238 | $13 |
| Prednisone | 21 | $108 | $5 |
| Acyclovir | 12 | $76 | $6 |
2014: 1 drug
| Anastrozole | 11 | $272 | $25 |
Money from drug and device companies
$31 in 2025
| 2025 | 1 | 1 | None | $31 |
| 2023 | 2 | 5 | None | $121 |
| 2022 | 1 | 3 | None | $58 |
| 2021 | 2 | 12 | None | $178 |
| 2020 | 3 | 5 | None | $98 |
| 2019 | 7 | 13 | None | $219 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Ibrance | $31 | 1 payment
|
See the published payment
| Pfizer | Education · 2025-09-23 | Ibrance | $31 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $121
| Pfizer | Ibrance | $96 | 4 payments
|
| Myriad Genetic Laboratories | Precisetumor | $25 | 1 payment
|
2022: $58
| Pfizer | Ibrance | $58 | 3 payments
|
2021: $178
| Pfizer | Inlyta | $138 | 9 payments
|
| Acrotech Biopharma | Beleodaq | $40 | 3 payments
|
2020: $98
| Pfizer | Inlyta | $40 | 3 payments
|
| Taiho Oncology | Lonsurf | $35 | 1 payment
|
| Genentech USA | Venclexta | $23 | 1 payment
|
2019: $219
| Pfizer | Bavencio | $81 | 6 payments
|
| Lilly USA | Erbitux | $36 | 2 payments
|
| Amgen | Nplate | $29 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Genentech USA | Venclexta | $18 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $18 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $16 | 1 payment
|
Professional record
- NPI
- 1326209438
- Licence
- CA A123342California A123342: Current · expires 2026-10-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 296448801
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 15400 National Ave, Suite 201, Los Gatos, CA, 95032
- NPI first listed
- 2008-06-20
- NPI last updated
- 2013-12-02
This is when the NPI record was last certified, not a medical board exam.